Pharmacology of Acamprosate: An Overview

CNS Drug Reviews

Volumn 9, Issue 4, 2003, Pages 359-374

  Zornoza, Teodoro ^a   Cano, María J ^a   Polache, Ana ^a   Granero, Luis ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Acamprosate; Alcoholism; Anticraving drugs; Drug addiction; Relapse

Indexed keywords

ACAMPROSATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALCOHOLISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG USE; INTESTINE ABSORPTION; NEUROBIOLOGY; NEUROPHARMACOLOGY; RELAPSE; REVIEW;

EID: 0347418926     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00260.x     Document Type: Review

References (69)

1. 2+ channels in cultured rat mesencephalic neurones. Naunyn-Schmiedeberg's Arch Pharmacol 2000;362:440-443.
2. Al-Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate: Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-814.
3. Al-Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001;25:1276-1283.
4. Al-Qatari M, Littleton J. Acamprosate inhibits the up-regulation of calcium channels in rat brain associated with development of ethanol dependence. Alcohol Clin Exp Res 1996;20:92A.
5. Anderberg EK, Lindmark T, Artursson P. Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route. Pharmac Res 1993;10:857-864.
6. B receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-191.
7. Blaha CD, Yang CR, Floresco SB, Barr AM, Phillips A. Stimulation of the ventral subiculum of the hippocampus evokes glutamate receptor-mediated changes in dopamine efflux in the rat nucleus accumbens. Eur J Neurosci 1997;5:902-911.
8. Boismare F, Daoust M, Moore ND, et al. A homotaurine derivate reduces the voluntary intake of ethanol by rats. Are cerebral GABA receptors involved? Pharmacol Biochem Behav 1984;21:787-789.
9. Brudzynski SM, Gibson CJ. Release of dopamine in the nucleus accumbens caused by stimulation of the subiculum in freely moving rats. Brain Res Bull 1997;42:303-308.
10. Cano-Cebrián MJ, Zornoza-Sabina T, Guerri C, Granero L, Polache A. Effect of non-ionic surfactants (polysorbate 80) on the intestinal absorption of acamprosate in the rat. Alcohol Alcohol 2001;36:505.
11. Cano-Cebrián MJ, Zornoza-Sabina T, Guerri C, Polache A, Granero L. Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 2003;367:119-125.
12. Chabenat C, Chretien P, Daoust M, et al. Physicochemical, pharmacological and pharmacokinetic study of a new gabaergic compound, calcium acetylhomotaurinate. Meth Find Exp Clin Pharmacol 1988;10:311-317.
13. Cole JC, Littleton J, Little HJ. Effects of repeated ethanol administration in the plus maze; a simple model for conditioned abstinence behaviour. Psychopharmacology 1999;142:270-279.
14. Cole JC, Littleton J, Little HJ. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze. Psychopharmacology 2000;147:403-411.
15. Czachowski CL, Legg BH, Samson HH. Effects of acamprosate on ethanol-seeking and self-administration in the rat. Alcohol Clin Exp Res 2001;25:344-350.
16. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res Neuroimaging 1998;82:107-114.
17. Dahchour A, De Witte P. Acamprosate decreases the hypermotility during repeated ethanol withdrawal. Alcohol 1999;18:77-81.
18. Dahchour A, De Witte P. Effects of acamprosate on excitatory amino acids during multiple ethanol withdrawal periods. Alcohol Clin Exp Res 2003;27:465-470.
19. Daoust M, Legrand E, Gewiss M, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992;41:669-674.
20. Daoust M, Prevost M, Saligaut C, et al. Calcium bis acetyl homotaurine increases the number of GABA uptake sites in alcohol prefering rat hippocampus. Alcohol Alcohol 1986;21:A31.
21. Durbin P, Belleville M. Rat pharmacokinetic profile of acamprosate in plasma, brain and CSF. Alcohol Alcohol 1995;30:548.
22. Fadda F, Rossetti ZL. Chronic ethanol consumption: from neuroadaptation to neurodegeneration. Prog Neurobiol 1998;56:385-431.
23. Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 2001;21:4915-4922.
24. Gibaldi M. Gastrointestinal absorption-Biological considerations. In: Gibaldi M, ed. Biopharmaceutics and Clinical Pharmacokinetics. Philadelphia: Lea and Febiger, 1991:25-39.
25. Grant KA, Woolverton D. Reinforcing and discriminative stimulus effects of calcium-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32:607-611.
26. Harris BR, Prendergast MA, Gibson A et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002;26:1779-1793.
27. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of polyethylene glycol and D-peptides. J Pharm Sci 1998;87:626-633.
28. Heyser CJ, Moc K, Koob GF. Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003;28:1463-1471.
29. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998;18:125-133.
30. Hölter SM, Landgraf R, Zieglgansberger W, Spanagel R. Time course of acamprosate action on operant self-administration after ethanol deprivation. Alcohol Clin Exp Res 1997;21:862-868.
31. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Psychopharmacology 2000;149:327-344.
32. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 2003;23:281-293.
33. Kratzer U, Schmidt WJ. Acamprosate does not induce a conditioned place preference and reveals no state-dependent effects in this paradigm. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:653-656.
34. Lê AD, Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol Ther 2002;94:137-156.
35. Legault M, Rompré PP, Wise R. Chemical stimulation of the ventral hippocampus elevates nucleus accumbens dopamine by activating dopaminergic neurons of the ventral tegmental area. J Neurosci 2000;20:1635-1642
36. Legault M, Wise R. Injections of N-methyl-D-aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse 1999;31:241-249
37. LeMagnen J, Tran G, Durlach J, Martin C. Dose-dependent supression of the high alcohol intake of chronically intoxicated rats by Ca-acetylhomotaurinate. Alcohol 1987;4:97-102.
38. Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1(8436):1014-1016.
39. Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613-622.
40. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther 1998;284:362-369
41. Littleton J. Acamprosate in alcohol dependence: How does it work? Addiction 1995;90:1179-1188.
42. McGeehan AJ, Olive MF. The anti-relapse compound acamprosate inhibits the development of a conditioned preference to ethanol and cocaine but not morphine. Br J Pharmacol 2003;138:9-12.
43. Mas-Serrano P, Granero L, Martin-Algarra RV, Guerri C, Polache A. Kinetic study of acamprosate absorption in rat small intestine. Alcohol Alcohol 2000;4:324-330
44. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001;62(Suppl 20):42-48.
45. Mason BJ, Goodman AM, Dixon RM, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606.
46. Mayer S, Harris BR, Gibson A, et al. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res 2002;26:1468-1478.
47. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate: Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998;22:802-809.
48. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;437:55-61.
49. Putzke J, Spanagel R, Tolle TR, Zieglgansberger W. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol 1996;317:39-48.
50. Quertemont E, Brabant C, De Witte P. Acamprosate reduces context-dependent ethanol effects. Psychopharmacology 2002;164:10-18.
51. Rammes G, Mahal B, Putzke J, et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001;40:749-760.
52. Ripley TL, Little HJ. Effects on ethanol withdrawal hyperexcitability of chronic treatment with a competitive N-methyl-D-aspartate receptor antagonist. J Pharmacol Exp Ther 1995;272:112-118.
53. Rossetti ZL, Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 1995;283:177-183.
54. Saas H, Soyka M, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-680.
55. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331-345
56. Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholics. Results from a non-blind, multicenter study. Drugs Res Dev 2002;3:1-12.
57. Spanagel R, Hölter SM. Pharmacological validation of a new animal model of alcoholism. J Neural Transm 2000;107:669-680.
58. Spanagel R, Hölter SM, Allingham K, Landgraf R. Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996;305:39-44.
59. Spanagel R, Zieglgansberger W, Hundt W. Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat. Eur J Pharmacol 1996;305:51-56.
60. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: New pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997;18:54-59.
61. Stromberg MF, Mackler SA, Volpicelli JR, O'Brien CP. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. Alcohol 2001;23:109-116.
62. 1 receptors. Psychopharmacology 2000;151:242-251
63. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: Recent advances and challenges. J Neurosci 2002;22:3332-3337.
64. Whitworth AB. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-1442.
65. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 1997;56:1038-53
66. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W. Acamprosate decreases postsynaptic potentials in the rat neocortex: Possible role of excitatory amino acid receptors. Eur J Pharmacol 1993;23:47-52.
67. Zieglgansberger W, Hauser C, Wetzel C, Putzke J, Siggins GR, Spanagel R. Actions of acamprosate on neurons of the central nervous system. In: Soyka M, ed. Acamprosate in relapse prevention of alcoholism. Berlin: Springer, 1996;65-70.
68. Zornoza-Sabina T, Cano-Cebrián MJ, Guerri C, Granero L, Polache A. Enhancement of acamprosate intestinal absorption by sodium caprate in the rat. Alcohol Alcohol 2001;36:469
69. Zornoza T, Guerri C, Polache A, Granero L. Disposition of acamprosate in the rat: influence of probenecid. Biopharm Drug Dispos 2002;23:283-291.